Cargando…

Is NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein–Protein Interactions?

[Image: see text] Modulation of protein–protein interactions (PPIs) with small molecules has been hampered by a lack of lucid methods capable of reliably identifying high-quality hits. In fragment screening, the low ligand efficiencies associated with PPI target sites pose significant challenges to...

Descripción completa

Detalles Bibliográficos
Autores principales: Dias, David M., Van Molle, Inge, Baud, Matthias G. J., Galdeano, Carles, Geraldes, Carlos F. G. C., Ciulli, Alessio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891296/
https://www.ncbi.nlm.nih.gov/pubmed/24436777
http://dx.doi.org/10.1021/ml400296c
_version_ 1782299362742763520
author Dias, David M.
Van Molle, Inge
Baud, Matthias G. J.
Galdeano, Carles
Geraldes, Carlos F. G. C.
Ciulli, Alessio
author_facet Dias, David M.
Van Molle, Inge
Baud, Matthias G. J.
Galdeano, Carles
Geraldes, Carlos F. G. C.
Ciulli, Alessio
author_sort Dias, David M.
collection PubMed
description [Image: see text] Modulation of protein–protein interactions (PPIs) with small molecules has been hampered by a lack of lucid methods capable of reliably identifying high-quality hits. In fragment screening, the low ligand efficiencies associated with PPI target sites pose significant challenges to fragment binding detection. Here, we investigate the requirements for ligand-based NMR techniques to detect rule-of-three compliant fragments that form part of known high-affinity inhibitors of the PPI between the von Hippel–Lindau protein and the alpha subunit of hypoxia-inducible factor 1 (pVHL:HIF-1α). Careful triaging allowed rescuing weak but specific binding of fragments that would otherwise escape detection at this PPI. Further structural information provided by saturation transfer difference (STD) group epitope mapping, protein-based NMR, competitive isothermal titration calorimetry (ITC), and X-ray crystallography confirmed the binding mode of the rescued fragments. Our findings have important implications for PPI druggability assessment by fragment screening as they reveal an accessible threshold for fragment detection and validation.
format Online
Article
Text
id pubmed-3891296
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-38912962014-01-14 Is NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein–Protein Interactions? Dias, David M. Van Molle, Inge Baud, Matthias G. J. Galdeano, Carles Geraldes, Carlos F. G. C. Ciulli, Alessio ACS Med Chem Lett [Image: see text] Modulation of protein–protein interactions (PPIs) with small molecules has been hampered by a lack of lucid methods capable of reliably identifying high-quality hits. In fragment screening, the low ligand efficiencies associated with PPI target sites pose significant challenges to fragment binding detection. Here, we investigate the requirements for ligand-based NMR techniques to detect rule-of-three compliant fragments that form part of known high-affinity inhibitors of the PPI between the von Hippel–Lindau protein and the alpha subunit of hypoxia-inducible factor 1 (pVHL:HIF-1α). Careful triaging allowed rescuing weak but specific binding of fragments that would otherwise escape detection at this PPI. Further structural information provided by saturation transfer difference (STD) group epitope mapping, protein-based NMR, competitive isothermal titration calorimetry (ITC), and X-ray crystallography confirmed the binding mode of the rescued fragments. Our findings have important implications for PPI druggability assessment by fragment screening as they reveal an accessible threshold for fragment detection and validation. American Chemical Society 2013-11-03 /pmc/articles/PMC3891296/ /pubmed/24436777 http://dx.doi.org/10.1021/ml400296c Text en Copyright © 2013 American Chemical Society Terms of Use CC-BY (http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html)
spellingShingle Dias, David M.
Van Molle, Inge
Baud, Matthias G. J.
Galdeano, Carles
Geraldes, Carlos F. G. C.
Ciulli, Alessio
Is NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein–Protein Interactions?
title Is NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein–Protein Interactions?
title_full Is NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein–Protein Interactions?
title_fullStr Is NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein–Protein Interactions?
title_full_unstemmed Is NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein–Protein Interactions?
title_short Is NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein–Protein Interactions?
title_sort is nmr fragment screening fine-tuned to assess druggability of protein–protein interactions?
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891296/
https://www.ncbi.nlm.nih.gov/pubmed/24436777
http://dx.doi.org/10.1021/ml400296c
work_keys_str_mv AT diasdavidm isnmrfragmentscreeningfinetunedtoassessdruggabilityofproteinproteininteractions
AT vanmolleinge isnmrfragmentscreeningfinetunedtoassessdruggabilityofproteinproteininteractions
AT baudmatthiasgj isnmrfragmentscreeningfinetunedtoassessdruggabilityofproteinproteininteractions
AT galdeanocarles isnmrfragmentscreeningfinetunedtoassessdruggabilityofproteinproteininteractions
AT geraldescarlosfgc isnmrfragmentscreeningfinetunedtoassessdruggabilityofproteinproteininteractions
AT ciullialessio isnmrfragmentscreeningfinetunedtoassessdruggabilityofproteinproteininteractions